Melatonin as adjunctive therapy in patients admitted to the Covid-19
Karimpour-razkenari et al.,
Melatonin as adjunctive therapy in patients admitted to the Covid-19,
Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103492
Retrospective 31 ICU patients, 12 treated with melatonin, showing lower mortality with treatment, without statistical significance. Melatonin 15mg daily.
Although the 39% lower mortality is not statistically significant, it is consistent with the significant 48% lower mortality
[27‑63%] from meta analysis of the
9 mortality results to date.
risk of death, 39.0% lower, HR 0.61, p = 0.37, treatment 5 of 12 (41.7%), control 13 of 19 (68.4%), NNT 3.7, Kaplan–Meier.
|
ventilation time, 42.9% lower, relative time 0.57, p = 0.13, treatment 12, control 19.
|
ICU time, 1.9% lower, relative time 0.98, p = 0.85, treatment 12, control 19.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Karimpour-razkenari et al., 10 Mar 2022, retrospective, Iran, peer-reviewed, 6 authors, study period 13 March, 2020 - 30 May, 2020.
Abstract: Journal Pre-proof
Melatonin as adjunctive therapy in patients admitted to the Covid-19
Elahe Karimpour-razkenari, Fahimeh Naderi-Behdani, Ali Salahshoor, Fatemeh
Heydari, Abbas Alipour, Afshin Gholipour Baradari
PII:
S2049-0801(22)00252-7
DOI:
https://doi.org/10.1016/j.amsu.2022.103492
Reference:
AMSU 103492
To appear in:
Annals of Medicine and Surgery
Received Date: 1 February 2022
Revised Date:
3 March 2022
Accepted Date: 6 March 2022
Please cite this article as: Karimpour-razkenari E, Naderi-Behdani F, Salahshoor A, Heydari F, Alipour
A, Baradari AG, Melatonin as adjunctive therapy in patients admitted to the Covid-19, Annals of
Medicine and Surgery (2022), doi: https://doi.org/10.1016/j.amsu.2022.103492.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
Abstract
Objective: Coronavirus has disrupted the natural order of the world since September 2019 with
no specific medication. The beneficial effects of melatonin on sepsis and viral influenza were
demonstrated previously, but its effects on covid-19, especially COVID -19 ICU, is unclear.
Therefore, our aim was to determine the effects of melatonin in COVID-19 ICU patients.
Methods: This is a retrospective cohort study in which the records of patients admitted to
COVID -19 ICU of (XXX) during March to June 2020 were reviewed. According to inclusion
of
criteria, patients who received 15 mg of melatonin daily were called MRG and the rest were
ro
called NMRG.
-p
Results: Thirty-one patients were included and analyzed, of which twelve patients were in
re
MRG. Demographic and clinical characteristics, and laboratory data were similar between two
lP
groups at ICU admission. Melatonin had no significant effect on ICU duration, CRP and ESR,
also the trend of changes was in favor of melatonin. Nevertheless, melatonin significantly
na
reduced the NLR (OR=-9.81, p=0.003), and also declined mortality marginally (p=0.09).
Melatonin was well tolerated with no major adverse effects, moreover the thrombocytopenia
ur
occurrence was significantly lower in MRG (p=0.005). In MRG, survival increased and
Jo
mortality risk decreased, although the difference between groups wasn’t significant (p=0.37),
which might be related to the small sample-size.
Conclusion: Our study showed that melatonin is unlikely to reduce mortality among COVID19
patients and with no significant effect on disease-specific biochemical parameters.
Keywords: melatonin, COVID -19, Mortality, thrombocytopenia
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit